DK1085907T3 - Opløsning indeholdende prostaglandiner og benzylalkohol - Google Patents

Opløsning indeholdende prostaglandiner og benzylalkohol

Info

Publication number
DK1085907T3
DK1085907T3 DK99935286T DK99935286T DK1085907T3 DK 1085907 T3 DK1085907 T3 DK 1085907T3 DK 99935286 T DK99935286 T DK 99935286T DK 99935286 T DK99935286 T DK 99935286T DK 1085907 T3 DK1085907 T3 DK 1085907T3
Authority
DK
Denmark
Prior art keywords
benzyl alcohol
solution containing
containing prostaglandins
prostaglandins
new formulations
Prior art date
Application number
DK99935286T
Other languages
English (en)
Inventor
Robert G Re
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK1085907T3 publication Critical patent/DK1085907T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99935286T 1998-06-17 1999-06-08 Opløsning indeholdende prostaglandiner og benzylalkohol DK1085907T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/094,985 US6187818B1 (en) 1998-06-17 1998-06-17 Prostaglandins formulation and process
PCT/US1999/011808 WO1999065527A1 (en) 1998-06-17 1999-06-08 Solution comprising prostaglandins and benzyl alcohol

Publications (1)

Publication Number Publication Date
DK1085907T3 true DK1085907T3 (da) 2004-06-21

Family

ID=22248341

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99935286T DK1085907T3 (da) 1998-06-17 1999-06-08 Opløsning indeholdende prostaglandiner og benzylalkohol

Country Status (14)

Country Link
US (1) US6187818B1 (da)
EP (1) EP1085907B1 (da)
JP (1) JP4472175B2 (da)
KR (1) KR100608176B1 (da)
CN (1) CN1188170C (da)
AT (1) ATE263576T1 (da)
AU (1) AU752047B2 (da)
CA (1) CA2331284C (da)
DE (1) DE69916266T2 (da)
DK (1) DK1085907T3 (da)
ES (1) ES2219036T3 (da)
NZ (1) NZ508947A (da)
PT (1) PT1085907E (da)
WO (1) WO1999065527A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CN108078998B (zh) * 2017-11-23 2018-09-21 宁波三生生物科技有限公司 一种氨基丁三醇前列腺素F2α注射液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885041A (en) * 1970-12-28 1975-05-20 Searle & Co Antiinflammatory use of prostaglandins
US3917864A (en) 1973-02-12 1975-11-04 Sultanali M M Karim Use of prostaglandins E and F for induction of labor
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
EP0268066A3 (en) 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
HK1036413A1 (en) 2002-01-04
KR20010052944A (ko) 2001-06-25
KR100608176B1 (ko) 2006-08-04
DE69916266T2 (de) 2005-03-10
AU5079699A (en) 2000-01-05
EP1085907A1 (en) 2001-03-28
CN1188170C (zh) 2005-02-09
WO1999065527A1 (en) 1999-12-23
ES2219036T3 (es) 2004-11-16
ATE263576T1 (de) 2004-04-15
AU752047B2 (en) 2002-09-05
EP1085907B1 (en) 2004-04-07
CA2331284A1 (en) 1999-12-23
NZ508947A (en) 2003-05-30
PT1085907E (pt) 2004-08-31
JP2002518348A (ja) 2002-06-25
CA2331284C (en) 2009-09-22
JP4472175B2 (ja) 2010-06-02
DE69916266D1 (de) 2004-05-13
CN1301178A (zh) 2001-06-27
US6187818B1 (en) 2001-02-13

Similar Documents

Publication Publication Date Title
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
PT758248E (pt) Formulacoes para o factor ix
ES2130420T3 (es) Preparado transdermico de sustancia activa.
MX9603560A (es) Composiciones de prostaglandinas estables en almacenamiento.
NO304261B1 (no) Preparat omfattende en lipofil forbindelse
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
NZ294464A (en) Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products
CR11283A (es) "composicion de liberacion sostenida y proceso para producirla"
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
FI92648C (fi) Menetelmä peroraalisen terapeuttisen järjestelmän valmistamiseksi vaikeasti liukeneville vaikuttaville aineille
NO970051L (no) Vandige risperidon formuleringer
DK1248613T3 (da) Clonidinpræparater
NO20004721L (no) Bruseformuleringer
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
DE59800863D1 (de) Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
DK1085907T3 (da) Opløsning indeholdende prostaglandiner og benzylalkohol
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
NZ337798A (en) Pharmaceutical compositions containing lamivudine
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
NO975634L (no) Stabile farmasöytiske preparater inneholdende tiludronathydrater og fremgangsmåte for fremstilling av farmasöytiske preparater
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
AU618896B2 (en) Stable solutions of rebeccamycin analog and preparation thereof